文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

阿替普酶治疗COVID-19重度低氧性呼吸衰竭:TRISTARDS多中心随机试验

Alteplase in COVID-19 severe hypoxemic respiratory failure: the TRISTARDS multicenter randomized trial.
PubMed 文献 · Ann Intensive Care · 2024-11-10
一句话结论阿替普酶未能加快COVID-19重度低氧性呼吸衰竭的临床恢复,但观察到生存率和PaO2/FiO2的数值差异,尤其未接受有创通气的患者。

TRISTARDS多中心开放标签随机试验纳入COVID-19重度低氧性呼吸衰竭患者,比较阿替普酶(低剂量或高剂量)5天联合标准治疗与单纯标准治疗。主要终点至第28天临床改善时间在阿替普酶组为25天,标准治疗组>28天(中位数未达到)。第28天全因死亡率阿替普酶组8/69(12%)vs 标准治疗组10/35(29%),未校正风险差-17%(95%CI -34至0),p=0.047;校正风险差-16%(95%CI -31至1),p=0.058。PaO2/FiO2比值阿替普酶组平均增加30(84)mmHg,标准治疗组降低12(59)mmHg(校正均数差 vs 标准治疗,p=0.052)。大出血阿替普酶组9例 vs 标准治疗组0例,无致命性出血;因招募不足提前终止。

要点

  • 阿替普酶组至第28天临床改善中位时间25天,标准治疗组>28天(中位数未达到)。
  • 第28天全因死亡率阿替普酶组8/69(12%)vs 标准治疗组10/35(29%),未校正RD -17%(95%CI -34至0),p=0.047;校正RD -16%(95%CI -31至1),p=0.058。
  • PaO2/FiO2比值阿替普酶组平均增加30(84)mmHg,标准治疗组降低12(59)mmHg(校正均数差 vs 标准治疗,p=0.052)。
  • 阿替普酶组大出血9例 vs 标准治疗组0例,无致命性出血;阿替普酶组18例(26.1%)因不良事件停药。
  • 差异在高剂量阿替普酶组和未接受有创通气的患者中更大。

适用人群与场景

  • COVID-19重度低氧性呼吸衰竭患者;基线时65%使用高流量氧疗或无创通气。

处置流程与药物剂量

  • 阿替普酶(低剂量或高剂量)静脉给药5天,联合标准治疗;对照为单纯标准治疗。

研究设计与关键结果

  • 多中心、开放标签随机试验,纳入69例阿替普酶组(低剂量或高剂量)和35例标准治疗组;主要终点为至第28天临床改善时间(WHO临床进展量表评分下降≥2分或出院)。
  • 至第28天临床改善中位时间:阿替普酶组25天 vs 标准治疗组>28天(中位数未达到)。
  • 第28天全因死亡率:阿替普酶组8/69(12%)vs 标准治疗组10/35(29%);未校正风险差-17%(95%CI -34至0),p=0.047;校正风险差-16%(95%CI -31至1),p=0.058。
  • 第6天PaO2/FiO2比值较基线变化:阿替普酶组平均增加30(84)mmHg vs 标准治疗组降低12(59)mmHg;校正均数差 vs 标准治疗,p=0.052。
  • 差异在高剂量阿替普酶组和未接受有创通气的患者中更大。
  • 阿替普酶组18例(26.1%)因不良事件停药;大出血阿替普酶组9例 vs 标准治疗组0例,无致命性出血。
  • 研究因患者招募不足提前终止。

证据类型、等级与局限

  • 随机对照试验(多中心、开放标签),因招募不足提前终止。
  • 局限:研究因患者招募不足提前终止;作者指出这些探索性发现需要在更大样本队列中进一步研究,以验证本研究提出的关于阿替普酶对治疗结局影响的假设。

对床旁实践的改变

  • 阿替普酶未显示加快COVID-19重度低氧性呼吸衰竭的临床恢复。
  • 作者认为,生存率和PaO2/FiO2比值的数值差异,尤其在不接受有创通气的患者中,值得在更大样本队列中进一步研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Pulmonary intravascular thrombus formation has been widely observed in patients with respiratory failure, for example, in patients with SARS-CoV-2 infection (COVID-19). The aim of this study was to evaluate the efficacy/safety of alteplase thrombolysis in COVID-19 severe hypoxemic respiratory failure. In this multicenter, open-label study, patients were randomized to receive alteplase (low- or high-dose) over 5 days plus standard of care (SOC), or SOC alone. The primary endpoint was time to clinical improvement (≥ 2-point decrease on WHO Clinical Progression Scale, or hospital discharge) up to Day 28. Secondary endpoints included all-cause mortality at Day 28, treatment failure at Day 28 and change in arterial oxygen partial pressure/fractional inspired oxygen (PaO2/FiO2) ratio at Day 6 versus baseline.

RESULTS: Sixty-nine patients were randomized to alteplase (low- or high-dose) and 35 to SOC; 65% were on high-flow oxygen or non-invasive ventilation at baseline. Median time to clinical improvement was 25 days in the alteplase group and > 28 days (median not reached) in the SOC group. All-cause mortality was 8/69 (12%) versus 10/35 (29%) in the alteplase versus SOC groups, respectively (unadjusted risk difference [RD], - 17% [95% confidence interval (CI) - 34 to 0], p = 0.047; adjusted RD, - 16% [95% CI - 31 to 1], p = 0.058). The PaO2/FiO2 ratio (mean [standard deviation]) increased by + 30 (84) mmHg in the alteplase group and decreased by - 12 (59) mmHg in the SOC group (adjusted mean difference vs. SOC, p = 0.052). Differences were greater in patients receiving high-dose alteplase, and in those not receiving invasive ventilation. Eighteen patients (26.1%) in the alteplase group discontinued treatment due to adverse events. Major bleeding was more frequent with alteplase than with SOC (9 vs. 0 patients); no bleeding was fatal. The study closed early due to insufficient patient recruitment.

CONCLUSION: Alteplase was not associated with faster clinical recovery from COVID-19 severe hypoxemic respiratory failure. A numerical difference in survival and PaO2/FiO2 ratio was observed, particularly in patients not receiving invasive ventilation. These exploratory findings merit further investigation in larger patient cohorts that are adequately powered to confirm the hypotheses generated in this study regarding the impact of alteplase on treatment outcomes. Trial registration ClinicalTrials.gov: NCT04640194 (November 23, 2020); https://clinicaltrials.gov/study/NCT04640194 (early discontinuation due to insufficient patient recruitment).

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Landoni G, Chowdary P, Meziani F, et al. Alteplase in COVID-19 severe hypoxemic respiratory failure: the TRISTARDS multicenter randomized trial. Ann Intensive Care. 2024. PMID: 39522090. doi:10.1186/s13613-024-01386-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。